Sarepta Therapeutics Provides Update on ELEVIDYS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/31/2026

1. PCG
2. NVDA
3. AVGO
4. ALNY
5. CNS
6. ATTO
7. BRVE
8. EIX
9. EC
10. APO

Go back to Sarepta Therapeutics Provides Update on ELEVIDYS

Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)

April 4, 2025 12:28 PM EDT

Barclays analyst Gena Wang reiterated an Overweight rating and $209.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)

The analyst comments "Key takeaways. Following the EU's temporary halt of ongoing Elevidys studies due to recent safety update, SRPT provided another update on an independent data... More